Skip to main content

Advertisement

SpringerLink
Log in

Diabetic Nephropathy: Worldwide epidemic and effects of current treatment on natural history

  • Published:
Current Diabetes Reports Aims and scope Submit manuscript

Abstract

Diabetic nephropathy has become a worldwide epidemic, accounting for approximately one third of all cases of end-stage renal disease. With increasing prevalence of diabetes particularly in Asia, and a global prevalence of microalbuminuria of 39%, the problem is expected to grow. Improved management of diabetes aimed at improved glycemic control, to avoid initiation of diabetic nephropathy, and antihypertensive treatment blocking the renin-angiotensin system, to avoid its progression, need to be implemented, particularly in high-risk patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Krolewski AS, Warram JH, Christlieb AR, et al.: The changing natural history of nephropathy in type 1 diabetes. Am J Med 1985, 78:785–794.

    Article  PubMed  CAS  Google Scholar 

  2. Kofoed-Enevoldsen A, Borch-Johnsen K, Kreiner S, et al.: Declining incidence of persistent proteinuria in type 1 (insulin-dependent) diabetic patients in Denmark. Diabetes 1987, 36:205–209.

    Article  PubMed  CAS  Google Scholar 

  3. Bojestig M, Arnqvist HJ, Hermansson G, et al.: Declining incidence of nephropathy in insulin-dependent diabetes mellitus. N Engl J Med 1994, 330:15–18.

    Article  PubMed  CAS  Google Scholar 

  4. Rossing P: The changing epidemiology of diabetic microangiopathy in type 1 diabetes. Diabetologia 2005, 48:1439–1444.

    Article  PubMed  CAS  Google Scholar 

  5. United States Renal Data System: USRDS Annual Data Report 2004. Bethesda, MD: National Institute of Diabetes and Digestive and Kidney Diseases; 2004. Accessible online at http://www.usrds.org/adr_2004.htm.

    Google Scholar 

  6. Gilbertson DT, Liu J, Xue JL, et al.: Projecting the number of patients with end-stage renal disease in the United States to the year 2015. J Am Soc Nephrol 2005, 16:3736–3741.

    Article  PubMed  Google Scholar 

  7. Van Dijk PC, Jager KJ, Stengel B, et al.: Renal replacement therapy for diabetic end-stage renal disease: data from 10 registries in Europe (1991-2000). Kidney Int 2005, 67:1489–1499.

    Article  PubMed  Google Scholar 

  8. Cusumano AM, Di GC, Hermida O, Lavorato C: The Latin American Dialysis and Renal Transplantation Registry Annual Report 2002. Kidney Int Suppl 2005, Aug: S46–S52.

  9. Agarwal SK: Chronic kidney disease and its prevention in India. Kidney Int Suppl 2005, Aug: S41–S45.

  10. Parving HH, Lewis JB, Ravid M, et al.: Prevalence and risk factors for microalbuminuria in a referred cohort of type II diabetic patients: a global perspective. Kidney Int 2006, 69:2057–2063. Global study of the prevalence of microalbuminuria.

    Article  PubMed  Google Scholar 

  11. Wu AY, Kong NC, de Leon FA, et al.: An alarmingly high prevalence of diabetic nephropathy in Asian type 2 diabetic patients: the MicroAlbuminuria Prevalence (MAP) Study. Diabetologia 2005, 48:17–26.

    Article  PubMed  CAS  Google Scholar 

  12. Wild S, Roglic G, Green A, et al.: Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004, 27:1047–1053.

    Article  PubMed  Google Scholar 

  13. Saydah SH, Fradkin J, Cowie CC: Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA 2004, 291:335–342.

    Article  PubMed  CAS  Google Scholar 

  14. Jones CA, Krolewski AS, Rogus J, et al.: Epidemic of endstage renal disease in people with diabetes in the United States population: do we know the cause? Kidney Int 2005, 67:1684–1691.

    Article  PubMed  Google Scholar 

  15. Ballard DJ, Humphrey LL, Melton III LJ, et al.: Epidemiology of persistent proteinuria in type II diabetes mellitus. Population-based study in Rochester, Minnesota. Diabetes 1988, 37:405–412.

    Article  PubMed  CAS  Google Scholar 

  16. Rossing P, Gall MA, Hougaard P, Parving HH: Progression from normoalbuminuria to incipient diabetic nephropathy in type 1 and type 2 diabetic patients. Diabetologia 2003, 46:A31.

    Google Scholar 

  17. Kussman MJ, Goldstein HH, Gleason RE: The clinical course of diabetic nephropathy. JAMA 1976, 236:1861–1863.

    Article  PubMed  CAS  Google Scholar 

  18. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group [no authors listed]. N Engl J Med 1993, 329:977–986.

  19. Rossing P, Rossing K, Jacobsen P, Parving HH: Unchanged incidence of diabetic nephropathy in IDDM patients. Diabetes 1995, 44:739–743.

    Article  PubMed  CAS  Google Scholar 

  20. Chase HP, Garg SK, Marshall G, et al.: Cigarette smoking increases the risk of albuminuria among subjects with type 1 diabetes. JAMA 1991, 265:614–617.

    Article  PubMed  CAS  Google Scholar 

  21. Rossing P, Hougaard P, Parving HH: Risk factors for development of incipient and overt diabetic nephropathy in type 1 diabetic patients. Diabetes Care 2002, 25:859–864.

    Article  PubMed  Google Scholar 

  22. Hovind P, Tarnow L, Rossing K, et al.: Decreasing incidence of severe diabetic microangiopathy in type 1 diabetes. Diabetes Care 2003, 26:1258–1264.

    Article  PubMed  Google Scholar 

  23. Nishimura R, Dorman JS, Bosnyak Z, et al.: Incidence of ESRD and survival after renal replacement therapy in patients with type 1 diabetes: a report from the Allegheny County Registry. Am J Kidney Dis 2003, 42:117–124.

    Article  PubMed  Google Scholar 

  24. Dansk Nefrologisk Selskab (The Danish Society of Nephrology): Danish National Registry Report on Dialysis and Transplantation in Denmark 2004. Denmark: Paritas Gra.k A/S. Accessible online at http://www.nephrology. dk/Publikationer/Landsregister/Landsregisteret.2004.pdf.

  25. Burrows NR, Narva AS, Geiss LS, et al.: End-stage renal disease due to diabetes among southwestern American Indians, 1990–2001. Diabetes Care 2005, 28:1041–1044.

    Article  PubMed  Google Scholar 

  26. Pirart J: Diabetes mellitus and its degenerative complications: a prospective study of 4,400 patients observed between 1947 and 1973. Diabetes Care 1978, 1:168–188.

    Google Scholar 

  27. Wang PH, Lau J, Chalmers TC: Meta-analysis of effects of intensive blood-glucose control on late complications of type I diabetes. Lancet 1993, 341:1306–1309.

    Article  PubMed  CAS  Google Scholar 

  28. Parving HH, Andersen AR, Smidt UM, Svendsen PA: Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy. Lancet 1983, 1:1175–1179.

    Article  PubMed  CAS  Google Scholar 

  29. Mogensen CE: Long-term antihypertensive treatment inhibiting progression of diabetic nephropathy. BMJ 1982, 285:685–688.

    Article  PubMed  CAS  Google Scholar 

  30. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993, 329:1456–1462.

    Article  PubMed  CAS  Google Scholar 

  31. Parving HH, Lehnert H, Brochner-Mortensen J, et al.: The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001, 345:870–878.

    Article  PubMed  CAS  Google Scholar 

  32. Rossing K, Christensen PK, Andersen S, et al.: Comparative effects of irbesartan on ambulatory and office blood pressure: a substudy of ambulatory blood pressure from the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study. Diabetes Care 2003, 26:569–574.

    Article  PubMed  CAS  Google Scholar 

  33. Lewis EJ, Hunsicker LG, Clarke WR, et al.: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001, 345:851–860.

    Article  PubMed  CAS  Google Scholar 

  34. Brenner BM, Cooper ME, de Zeeuw D, et al.: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001, 345:861–869.

    Article  PubMed  CAS  Google Scholar 

  35. Chaturvedi N: Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. Lancet 1997, 349:1787–1792.

    Article  Google Scholar 

  36. Ruggenenti P, Fassi A, Ilieva AP, et al.: Preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004, 351:1941–1951.

    Article  PubMed  CAS  Google Scholar 

  37. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators [no authors listed]. Lancet 2000, 355:253–259.

  38. Chaturvedi N: Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin-converting enzyme inhibitors? A meta-analysis of individual patient data. Ann Intern Med 2001, 134:370–379.

    Google Scholar 

  39. Mathiesen ER, Hommel E, Hansen HP, et al.: Preservation of normal GFR with long term captopril treatment in normotensive IDDM patients with microalbuminuria. BMJ 1999, 319:24–25.

    PubMed  CAS  Google Scholar 

  40. Gaede P, Vedel P, Larsen N, et al.: Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003, 348:383–393. First study to demonstrate beneficial effect of multifactorial intervention in high-risk type 2 diabetic patients.

    Article  PubMed  Google Scholar 

  41. Knowles HCJ: Long-term juvenile diabetes treated with unmeasured diet. Trans Assoc Am Physicians 1971, 84:95–101.

    PubMed  Google Scholar 

  42. Andersen AR, Christiansen JS, Andersen JK, et al.: Diabetic nephropathy in type 1 (insulin-dependent) diabetes: an epidemiological study. Diabetologia 1983, 25:496–501.

    Article  PubMed  CAS  Google Scholar 

  43. Parving HH, Jacobsen P, Rossing K, et al.: Benefits of longterm antihypertensive treatment on prognosis in diabetic nephropathy. Kidney Int 1996, 49:1778–1782.

    Article  PubMed  CAS  Google Scholar 

  44. Rossing P, Hougaard P, Borch-Johnsen K, Parving HH: Predictors of mortality in insulin dependent diabetes: 10 year follow-up study. BMJ 1996, 313:779–784.

    PubMed  CAS  Google Scholar 

  45. Astrup AS, Tarnow L, Rossing P, et al.: Improved prognosis in type 1 diabetic patients with nephropathy: a prospective follow-up study. Kidney Int 2005, 68:1250–1257.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Steno Diabetes Center, Niels Steensens Vej 2, 2820, Gentofte, DK, Denmark

    Peter Rossing MD, DMSC

Authors
  1. Peter Rossing MD, DMSC
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Peter Rossing MD, DMSC.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rossing, P. Diabetic Nephropathy: Worldwide epidemic and effects of current treatment on natural history. Curr Diab Rep 6, 479–483 (2006). https://doi.org/10.1007/s11892-006-0083-y

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11892-006-0083-y

Keywords

Search

Navigation